Avai Bio Q1 FY27 net loss widens 13% to $552,041; revenue remains no revenue
AVAI•Avai Bio reports wider quarterly loss and no revenue
- Avai Bio posted a net loss of $552,041 for the quarter ended June 30, 2026, widening 13%.
- Operating loss narrowed 13.9% to $419,783; operating expenses fell to $419,783 on lower marketing and professional fees.
- Other expenses swung to $132,258 from none, driven by interest and discount on convertible notes, loan interest, and a loss on disposal.
- Cash rose to $83,586; working capital deficit widened to $3.86 million.
- Net cash used in operations increased to $414,258; financing cash inflows climbed to $533,299.
Related News
Cingulate Q2 FY26 net loss widens to $5.87 million; SG&A more than doubles to $3.93 million
CING•
Candel Therapeutics Q2 FY26 net loss widens to $38.9 million; R&D expense more than doubles to $19.8 million
CADL•
